Eclampsia, preeclampsia, and hypertension
Education on Eclampsia, preeclampsia, and hypertension and Alpha-1 Antitrypsin research from the Mark Egly Foundation, with patent claims clearly labeled as hypothesis.
Research hypothesis, not medical advice
The connections described on this page come from Mark Egly's patent filing and ongoing research. They are not established medical facts. Always work with your physician for diagnosis and treatment.
Research hypothesis. The connection between Eclampsia, preeclampsia, and hypertension and Alpha-1 Antitrypsin is described in Mark Egly's 2020 patent filing. This is not established medical fact and is not medical advice. Always talk with your doctor about your own health.
What is Eclampsia, preeclampsia, and hypertension?
Eclampsia, preeclampsia, and hypertension is a health condition discussed in Mark Egly's research on Alpha-1 Antitrypsin. Maternal conditions affect pregnancy and maternal health.
What Mark Egly's patent discusses
Eclampsia and preeclampsia are characterized by high blood pressure in pregnant women, possibly leading to convulsions or stroke. Acute kidney and liver failure can occur in the mother, and the infant can suffer severe hypoxia. A link between neutrophil extracellular traps ("NETs") and several conditions including preeclampsia was shown by Brinkmann and Zychlinsky. Further connections between neutrophils and preeclampsia were shown by Leik and Walsh, by Canzoneri et al, and by Clark et al. Preeclampsia and its complications have become a leading cause of maternal and fetal morbidity and mortality. The development of preeclampsia is unpredictable; therefore, it is difficult to prevent and manage, yet a monitoring of circulating alpha1 antitrypsin throughout pregnancy can make it much more predictable and dealt with appropriately AAT can relieve medical situations that can cause high blood pressure or hypertension by reducing NETs that can clog blood vessels. By the elimination of NETs, the circulatory system can be maintained in a healthier state. AAT attaches to the excess neutrophils that cause NETs to form, and AAT assists with the safe elimination of NETs from the body. Oxidati…
How this may relate to Alpha-1
Mark Egly's patent proposes that when the body has too little working Alpha-1 Antitrypsin, or when neutrophils release too much neutrophil elastase, inflammation and tissue damage may worsen. For Eclampsia, preeclampsia, and hypertension, the patent suggests that testing for AATD or low circulating AAT could help guide care. This is a research hypothesis, not a proven treatment path for everyone with this condition.
What you can do
If you or a family member lives with Eclampsia, preeclampsia, and hypertension, consider learning about Alpha-1 Antitrypsin Deficiency and discussing AAT testing with your healthcare team. The Mark Egly Foundation offers education and community support: